PT  - JOURNAL ARTICLE
AU  - TOMOHIRO SERA
AU  - TAKASHI SAKUMA
AU  - KOJI MARUO
AU  - GEN TSUJIO
AU  - YURIE YAMAMOTO
AU  - ATSUSHI SUGIMOTO
AU  - SYUHEI KUSHIYAMA
AU  - SHINGO TOGANO
AU  - KENJI KURODA
AU  - HIROAKI KASASHIMA
AU  - MASAICHI OHIRA
AU  - KIYOSHI MAEDA
TI  - Candidate Oncogenes, <em>ARHGAP4, NOS3</em>, and <em>OR51B5</em>, for the Development of Scirrhous-type Gastric Cancer
AID  - 10.21873/anticanres.16026
DP  - 2022 Nov 01
TA  - Anticancer Research
PG  - 5195--5203
VI  - 42
IP  - 11
4099  - http://ar.iiarjournals.org/content/42/11/5195.short
4100  - http://ar.iiarjournals.org/content/42/11/5195.full
SO  - Anticancer Res2022 Nov 01; 42
AB  - Background/Aim: Scirrhous-type gastric cancer (SGC), one of the most intractable cancer subtypes, is characterized by rapid cancer cell proliferation and infiltration accompanied by extensive stromal fibrosis. One of the reasons for its poor prognosis may be the lack of molecular target drugs for SGC, because of the unknown driver genes. Exploration of somatic mutations in the human samples of SGC using next-generation sequencing (NGS) has been hampered by abundant fibrous tissues in these samples. Therefore, this study aimed to determine a novel oncogene by RNA-sequencing using SGC cell lines, avoiding contamination with fibrosis. Materials and Methods: In silico analysis of RNA-sequencing public data of the gastric cancer cell line, and RNA- sequencing using five of our unique SGC cell lines, OCUM1, OCUM2MLN, OCUM8, OCUM12, and OCUM14 were performed. Results: We found three differentially expressed genes, ARHGAP4, NOS3, and OR51B5 that are significantly over-expressed in SGC cells. Immunohistochemical analysis indicated that the protein expression levels of these three genes were significantly higher in SGC than in other types of gastric cancer. The prognosis of patients with positive expression of these three genes was significantly poorer than those with negative expression. In particular, ARHGAP4 expression was an independent predictor of poor prognosis and recurrence. Conclusion: ARHGAP4, NOS3, and OR51B5 may be candidate driver genes for SGC. ARHGAP4 may be a promising molecular target for SGC.